Background: Infliximab is effective maintenance for moderate to severe Crohn's disease (CD); however, problems with immunogenicity and decreased efficacy often complicate long-term use. Durability of infliximab maintenance therapy over multiple years has not been defined. ## Methods: This was a r
Vulval Crohn's disease: A tertiary center experience of 23 patients
โ Scribed by J. Landy; S.T.C. Peake; A. Akbar; A.L. Hart
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 36 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
โฆ Synopsis
s disease (CD) affecting the vulva is often unrecognized and can be difficult to treat. The majority of cases reported describe metastatic CD, where the vulval inflammation is not contiguous with the gastrointestinal tract. Overall, only 56 cases of vulval CD are reported in the literature since the first description by Parks et al in 1965. 1 We present our experience of 23 patients with vulval CD in a single tertiary center between 1999 and 2010. To our knowledge, this is the largest reported series of patients with vulval CD.
The inflammatory bowel disease (IBD) database was searched for all patients with a diagnosis of CD (based on standard clinical, endoscopic, and histological criteria), also affecting the vulva. Twenty-three patients were identified and their case notes were reviewed.
Five patients had metastatic vulval CD, while 18/23 had contiguous disease. Vulval involvement was the first presentation of CD for two patients. All of the patients were premenopausal and the median age at the time of vulval CD was 29 years (range, 19-50 years). The median interval from diagnosis of CD to vulval involvement was 10 years (range, 0-32 years).
The median age of CD diagnosis was 18 years (range, 13-40 years). Thirteen of the patients had previously undergone at least one surgical resection prior to their presentation of vulval disease. Seven had undergone proctocolectomy and four patients subtotal or hemicolectomy prior to presentation with vulval disease. Seventeen
๐ SIMILAR VOLUMES
Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require
## Background: The aim of this study was to evaluate the shortand long-term safety experience of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. ## Methods: The medical records of 297 consecutive patients with CD treated with infliximab at the Beth Israel Deacon
Background: Our primary aim was to determine if the rate of small bowel resection (SBR) has declined over time among Crohn's disease (CD) patients seen at a single academic institution. A secondary aim was to establish whether the indication for surgery has changed. ## Methods: Patients with a pr
## Background: The published experience regarding the use of tacrolimus in crohn's disease (cd) and ulcerative colitis (uc) refractory to more commonly used medical therapy has been fairly limited. our objective was to describe our experience with its use in a cohort of patients which, to our knowl
Background: 6-Thioguanine (6-TG) is efficacious in patients with Crohn's Disease (CD) failing conventional immunosuppression but there are reports of hepatotoxicity. We report our experience of the safety and efficacy of 6-TG in a series of patients with CD. Methods: A retrospective study of patien